Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — FY2021 Earnings Presentation
53 slides from Aspen Pharmacare's earnings presentation, September 2021
Slide 1: Year End Results Presentation
Year End Results Presentation For the 12 months ended 30 June 2021
Slide 2: Disclaimer
DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S.
Slide 3: Disclosure Note
DISCLOSURE NOTE RESTATEMENT OF DISCONTINUED OPERATIONS Discontinued European Business The discontinued European business comprises the European Thrombosis Assets divested to Mylan until the date of disposal, being 27 November 2020, the costs relating to its disposal, related Thrombosis product dis
Slide 4: Financial Review
S a 5 a rag 8 1S) © © = pc
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Revenue Normalised HEPS CONTINUING (R'million) (Rands) +10% CER* +7% CER* DOUBLE-DIGIT ORGANIC REVENUE GROWTH SOLID EARNINGS GROWTH SHARP FURTHER REDUCTION IN BORROWINGS Net Borrowings ƚ (R'million) Dividend declared & Leverage ratio (x) ^ DIVIDEND REINSTATED, AS GUIDED 2.90x DE
Slide 6: Segmental Revenue
SEGMENTAL REVENUE CONTINUING R’MILLION Regional Brands Resilient performance despite negative +2% CER * COVID and EU oncology impact Sterile Focus Brands Sound underlying performance +9% CER * maintained, with some territories benefitting from COVID-related demand Manufacturing +7% CER* excluding FD
Slide 7: Gross Profit Percentage (CER)
GROSS PROFIT PERCENTAGE (CER*) CONTINUING Regional Brands Sterile Focus Brands H1 2021 cost saving Continued lower gains diluted by margin sales mix negative impact of affected margins in EU oncology price H2 2021 cuts in H2 2021 Manufacturing Group Low/no margin FDF Group gross profit transaction-r
Slide 8: Gross Profit Percentage Bridge (CER)
GROSS PROFIT PERCENTAGE BRIDGE (CER*) CONTINUING 50,9% 50,8% -0,1% -1,0% 0,5% -0,9% -1,6% -0,7% 47,1% Gross profit percentage FX Gross profit percentage Sterile Focus Brands Regional Brands Manufacturing Manufacturing - FDF Segmental mix Gross profit percentage 30 June 2020 30 June 2020 (CER) transa
Slide 9: Normalised EBITDA
NORMALISED EBITDA CONTINUING % of % of % change R'million FY 2021 revenue FY 2020 revenue % change CER* Operating expenses Gross profitǂ 17 789 47.1% 17 135 50.9% 4% 2% » Well controlled at reduced % of revenue » Targeted initiatives to continue in FY 2022 Depreciation 1 043 2.8% 940 2.8% 11% 8%
Slide 10: Currency Rate Variability Impact
CURRENCY RATE VARIABILITY IMPACT Key FY 2021 income statement measures conver ted at 27 August 2021 rates Demonstration of how results can be influenced by exchange rate fluctuations » Prior year reported results at H1 and H2 are at differing exchange rates » Exchange rates in current measurement
Slide 11: Normalised Headline Earnings Bridge
NORMALISED HEADLINE EARNINGS BRIDGE CONTINUING R’MILLION +10% +7% -92 5 978 456 -261 335 5 580 -78 38 5 455 South Africa 125 - ZAR 23% International - EUR 69% Normalised FX Normalised Headline Normalised EBITDA HPC Depreciation Amortisation Finance costs Tax Normalised Headline Earnings Earnings (CE
Slide 12: Operating Cash Flow
OPERATING CASH FLOW CONTINUING AND DISCONTINUED Operating cash conversion cycle Clearly defined cycle to operating cash conversion rates 200% Excellent cash generation in H2 2021 » Despite overhang from uncommonly low COVID-influenced FY 2020 150% year-end trade debtors » Year end working capita
Slide 13: Capital Expenditure
CAPITAL EXPENDITURE PPE capex* in R’million 2 442 2 039 2 045 2 000 PPE CAPEX* 1 600 First commercial production of Anaesthetics from strategic projects H2 2019 » Commenced for certain products at both Gqeberha and Bad 1 800 Oldesloe in FY 2021 » Notre Dame de Bondeville in FY 2023 COVID related
Slide 14: Borrowings
BORROWINGS Net Borrowings ƚ R’million 35 228 6 302 27 682 FY 2021 H1 2021 FY 2020 8 216 Gearing 19.9% 29.4% 33.7% 16 326 16 326 6 308 Interest cover ratio 8.57 6.78 6.53 36 019 29 259 24 606 Effective interest rate for the period ** 3.39% 3.24% 3.88% 18 564 266 -7 093 -9 793 -8 546 -8 546 FY 2020 H1
Slide 15: Capital Allocation Prioritisation – Report Back
CAPITAL ALLOCATION PRIORITISATION – REPORT BACK SUBJECT TO LEVERAGE CAP OF 3.0X PPE capex and Bolt-on acquisitions of Dividends Larger Acquisitions & IP development IP and businesses* Disposals Resumption of R735 million net dividends with R13 179 million net R2 681 million invested outflow R1 200 m
Slide 16: Group Chief Financial Officer Designate
GROUP CHIEF FINANCIAL OFFICER DESIGNATE INTRODUCING SEAN CAPAZORIO CA(SA), Advanced Certificate in Taxation Joined Aspen in 1999 through the acquisition of SA Druggists Financial director of Aspen’s South African business from 1999 to 2004 Group Business Analyst in corporate office from 2004
Slide 17: Performance Review
Performance Review
Slide 18: Aspen for Access
ASPEN FOR ACCESS Aspen has a core focus on equitable access to quality, affordable medicines Proud track record of delivery: ARVs, MDR-TB, dexamethasone & Anaesthetics for COVID Aspen produced the vaccine for J&J, with distribution to Africa and world Contributing to addressing current inequitab
Slide 19: ESG: Focusing Our Efforts Where It Matters
ESG: FOCUSING OUR EFFORTS WHERE IT MATTERS FY 2021 DEVELOPMENTS Capacity to manufacture up to 300 million doses of the Johnson & Johnson COVID vaccine Maintained a reliable supply of medicines Patients No market wide product recalls Signatory to the United Nations Women Empowerment Principle
Slide 20: Group Revenue
GROUP REVENUE CONTINUING % change R'million FY 2021 FY 2020 Reported CER * Commercial Pharma 27 874 26 366 6% 4% Regional Brands 17 183 16 751 3% 2% DOUBLE DIGIT REVENUE GROW TH IN BOTH REPORTED AND CER Sterile Focus Brands 10 691 9 615 11% 9% Manufacturing 9 892 7 293 36% 29% Group Revenue 37 766 3
Slide 21: Commercial Pharma | Regional Brands
COMMERCIAL PHARMA | REGIONAL BRANDS CONTINUING | REVENUE % change R’million FY 2021 FY 2020 Reported CER * Africa Middle East 8 057 7 911 2% 2% Americas 2 613 2 612 0% 9% RESILIENT PERFORMANCE DESPITE Asia 626 592 6% 4% COVID IMPACT Australasia 4 113 3 547 16% 6% Europe CIS 1 774 2 089 -15% -18% Reg
Slide 22: Commercial Pharma | Sterile Focus Brands
COMMERCIAL PHARMA | STERILE FOCUS BRANDS CONTINUING | REVENUE % change R’million FY 2021 FY 2020 Reported CER * Africa Middle East 513 457 12% 14% Americas 1 393 1 383 1% 9% CHINA BOOSTED BY POST-COVID Asia 4 491 3 728 20% 17% RECOVERY Australasia 754 683 10% 1% Europe CIS 3 540 3 364 5% 2% Sterile
Slide 23: Manufacturing Revenue
MANUFACTURING REVENUE CONTINUING | REVENUE % change R’million FY 2021 FY 2020 Reported CER * FDF 3 495 1 378 154% 142% API - Biochem 1 243 1 116 11% 6% INITIATION OF COVID-VACCINE REVENUE STREAM API- Chem 5 154 4 799 7% 2% Manufacturing 9 892 7 293 36% 29% Negative COVID impact greatest in Manufac
Slide 24: Sterile Strategy Update
i] i, teri Strategy pdate 6) aspen Healthcare. We Care. _-
Slide 25: J&J Has Partnered with Aspen on a Very Effective Vaccine
J&J HAS PARTNERED WITH ASPEN ON A VERY EFFECTIVE VACCINE DELIVERY OF THE J&J VACCINE ~96% of vaccinated individuals with breakthrough infections experience mild disease^ Impressive results from the Sisonke Trial 3.10% J&J effective and endures for at least 8 months 0.51% 0.46% ONE-SHOT VACCINE 9
Slide 26: Aspen Has a Deep Commitment to Capacitating Africa
ASPEN HAS A DEEP COMMITMENT TO CAPACITATING AFRICA UNLOCKING GLOBAL INEQUALITY TO ACCESS VACCINES Inequitable access to COVID vaccines globally » Nationalism and export restrictions » Those with capabilities and manufacturing, first access Africa negatively impacted despite having funding » 99%
Slide 27: Aspen's Vaccine Footprint in South Africa
ASPEN’S VACCINE FOOTPRINT IN SOUTH AFRICA Aspen converting existing vial capacity to include vaccine capabilities » Increases to vaccine capacity* • From 300 million doses to about 450 million doses by Feb 2022 • Over 700 million doses available by Jan 2023 • COVID-vaccines, boosters and other CMO
Slide 28: Sterile Capacity Utilization
STERILE CAPACITY UTILIZATION PROGRESS AT NOTRE DAME DE BONDEVILLE Available prefilled syringe capacity » 200 million doses • Balance allocated largely to Viatris and internal » High value add manufacture Volume commitment progress » Have signed/ far advanced with CMO contracts for three multinat
Slide 29: Reflections & Prospects
Reflections & Prospects ” Pie |
Slide 30: The Metamorphosis 2013 - 2021
THE METAMORPHOSIS 2013 - 2021 THE ASPEN MODEL Acquired » Significant sterile assets across Anaesthesia and Thrombosis • Substantial investment in leading global portfolios Expanded portfolios of branded assets » Enhanced geographic footprint » Critical mass across emerging markets API capabili
Slide 31: The Metamorphosis 2013 - 2021
THE METAMORPHOSIS 2013 - 2021 ACHIEVED TO DATE Revenue EBITDA + 96% + 68% Reshaped Commercial footprint » Clear organic growth drivers from reshape of portfolio towards growth territories » From commodity, generic focus to trusted brands with resilient margins » From presence in just 19 countries
Slide 32: A Positive Year for Aspen with Foundation Laid for Future Growth
A POSITIVE YEAR FOR ASPEN WITH FOUNDATION LAID FOR FUTURE GROWTH DELIVERING ON ORGANIC GROWTH TARGETS Produced, for J&J Reshaped Commercial Pharma Exchange rate impacted » COVID vaccine from Africa » Delivered solid organic revenue growth » H1 ↑ largely reversed by H2 ↓ » For Africa and the Gl
Slide 33: Corporate Activity
CORPORATE ACTIVITY Net Borrowings Reduction R’billion Continue to review composition of our portfolio » Regardless of debt balance » Against strategic objectives Objectives include, inter alia » Strategic fit to our existing portfolio » Leverage our distribution/ manufacturing footprint South
Slide 34: Prospects
PROSPECTS Commercial Pharma to sustain growth Unwinding of COVID lockdowns Growth drivers inverse of last year » Positive impact on manufacturing costs » Stronger growth in Regional Brands anticipated » Group EBITDA margins ↑ • Driven by Australasia and South Africa » Neutral on Commercial Pha
Slide 35: Prospects: To Rest Is to Rust
PROSPECTS Exchange rates will impact results » Vaccine sales are in hard currency Vaccine roll-out to gather momentum » FY 2021 had just 4 months of sales FY 2022 growth prospects – business as usual » High single digit revenue growth » Stronger EBITDA growth • Less COVID related costs » Even
Slide 36: Q&A
Q&A
Slide 37: Appendices
Appendices
Slide 38: Appendix 1: Strategic Positioning
APPENDIX 1: STRATEGIC POSITIONING BRANDED, SPECIALTY PRODUCT COMPLEX MANUFACTURING EXTENSIVE COMMERCIAL PORTFOLIO CAPABILITIES FOOTPRINT Sterile & Regional FDF & API Covering more than 50 countries Ongoing portfolio renewal through Leverage of installed capacity creates Delivering predictable annuit
Slide 39: Appendix 2: Strong Fundamentals for Organic Growth
APPENDIX 2: STRONG FUNDAMENTALS FOR ORGANIC GROWTH RESHAPED ASPEN’S ENHANCED COMMERCIAL ORGANIC GROWTH MANUFACTURING PHARMA DRIVERS CAPACITIES MODEL & CAPABILITIES COMMERCIAL PHARMA FUNDAMENTALS MANUFACTURING FUNDAMENTALS Focussed on territories with strong demographic Increasing demand for quality
Slide 40: Appendix 3: Energy & Water Plans for Sustainable Strategic Growth
APPENDIX 3: ENERGY & WATER PLANS FOR SUSTAINABLE STRATEGIC GROWTH SUSTAINABLE WATER STRATEGY SUSTAINABLE ENERGY STRATEGY Commencement of conservation Completed installation of solar panels practices from existing processes and (1MVA) and initiated smaller projects to ground water extraction, treatme
Slide 41: Appendix 4: Abridged Statement of Comprehensive Income
APPENDIX 4: ABRIDGED STATEMENT OF COMPREHENSIVE INCOME CONTINUING AND DISCONTINUED R’million FY 2021 FY 2020 % change Net revenue 39 705 40 536 -2% Cost of sales (21 515) (20 444) Gross profit 18 190 20 092 -9% Gross profit margin 45.8% 49.6% Operating expenses (9 959) (10 142) Net other operating e
Slide 42: Appendix 5: Abridged Statement of Normalised Comprehensive Income
APPENDIX 5: ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME CONTINUING FY 2020 R’million FY 2021 FY 2020 % change % change (CER*) (CER*) Net revenue 37 766 33 659 12% 34 395 10% Cost of sales (19 977) (16 524) 21% (16 920) 18% Gross profit 17 789 17 135 4% 17 475 2% Gross profit margin 47.1% 5
Slide 43: Appendix 6: Additional Borrowings-Related Disclosure
APPENDIX 6: ADDITIONAL BORROWINGS-RELATED DISCLOSURE CONTINUING Pro-forma maturity profile post syndicated loan extension Net funding costs R’million & IFC refinancing package ∂ R’million Continuing 19 580 R’million FY 2021 FY 2020 Net interest paid ( 854) (1 314) Foreign exchange (losses) ( 49) ( 8
Slide 44: Appendix 7: Reconciliation of Reported NHEPS
APPENDIX 7: RECONCILIATION OF REPORTED NHEPS CONTINUING AND DISCONTINUED Cents FY 2021 FY 2020 % change FY 2020 (CER) % change (CER*) Basic earnings per share (EPS) 1 052.9 1 021.8 3% 1 048.8 0% Impairment of property, plant and equipment 29.1 1.8 1.8 Impairment of intangible assets 274.8 280.6 296.
Slide 45: Appendix 8: Reconciliation of CER NHEPS
APPENDIX 8: RECONCILIATION OF CER* NHEPS CONTINUING Cents FY 2021 FY 2020 % change FY 2020 (CER) % change (CER*) Basic earnings per share (EPS) 1 051.1 740.5 42% 749.6 40% Impairment of property, plant and equipment 29.1 1.8 1.8 Impairment of intangible assets 274.8 280.6 296.1 Impairment of financi
Slide 46: Appendix 9: Currency Volatility
APPENDIX 9: CURRENCY VOLATILITY 6-month average exchange rates 6-month average exchange rates indexed to 100 (H1 2020 = 100) Market Average to end of H1 2020 H2 2020 H1 2021 H2 2021 currencies 27 August 2021 120 EURZAR 16.30 18.37 19.19 18.36 17.37 110 AUDZAR 10.05 10.94 11.75 11.48 10.77 100 USDZAR
Slide 47: Appendix 10.1: Group Statement of Financial Position
APPENDIX 10.1: GROUP STATEMENT OF FINANCIAL POSITION R'million FY 2021 FY 2020 TOTAL ASSETS Non-current assets 76 979 96 431 Intangible assets 54 882 73 040 Property, plant and equipment 14 826 14 232 Right-of-use assets 400 601 Goodwill 4 621 5 375 Deferred tax assets 1 323 1 714 Contingent environ
Slide 48: Appendix 10.2: Group Statement of Financial Position
APPENDIX 10.2: GROUP STATEMENT OF FINANCIAL POSITION R‘million FY 2021 FY 2020 EQUITY AND LIABILIITIES Shareholders equity 65 627 69 217 Non-current liabilities 7 306 45 873 Borrowings 266 36 019 Other non-current liabilities 3 732 4 957 Unfavourable and onerous contracts 463 927 Deferred tax liabil
Slide 49: Appendix 11: Working Capital Reconciliation
APPENDIX 11: WORKING CAPITAL RECONCILIATION FY 2021 FY 2020 H1 2021 Net working capital - Reported 13 971 18 049 16 408 Less Discontinued operations - (1 204) - Net working capital - Restated 13 971 16 845 16 408 Fx impact - (2 125) (647) Comparable base net working capital (CER) 13 971 14 720 15 76
Slide 50: Appendix 12: Net Working Capital Bridge (CER)
APPENDIX 12: NET WORKING CAPITAL BRIDGE (CER*) R’MILLION 18 049 -1 204 Cash movement -2 125 - R648 14 720 280 -348 -580 13 971 -101 FY 2020 Disposal related FX FY 2020 (CER, Inventories Trade debtors Trade creditors Non-cash FY 2021 included in FY2020 comparable base) * CER removes the currency effe
Slide 51: Appendix 13: Net Borrowings Bridge
APPENDIX 13: NET BORROWINGS BRIDGE R’MILLION 35 228 -2 473 32 755 -13 179 16 326 159 South Africa - ZAR -6 825 2 681 23% 735 International - EUR 69% Net borrowings as FX Net borrowings as Transaction related Cashflows from Bolt-ons (net disposals) Capex (IP Other Net Borrowings at 30 June 2020 at 30
Slide 52: Appendix 14: Leverage Ratio Calculation
APPENDIX 14: LEVERAGE RATIO CALCULATION BASED ON MAJOR AGREED TERMS INCLUDED IN THE FACILITIES AGREEMENT Net debt / EBITDA facilities agreement calculation Net debt = Gross borrowings - Cash + Lease liabilities + Non-contingent deferred payables* Adjusted for: difference between year end FX rates an
Slide 53: Thank You
Thank You 2
Aspen Pharmacare Holdings — FY2021 Earnings Presentation on 6ix